Business Wire

EXPEREO

31.1.2024 09:01:28 CET | Business Wire | Press release

Share
Expereo launches Enhanced Internet, the world’s first AI driven & fully internet-based solution to improve application performance globally

Expereo, the intelligent internet company that connects people, places and things anywhere, today launched its Enhanced Internet service, the first and only AI-driven solution that continually monitors the 100,000 networks that make up the internet and predicts the best performing route for companies’ network traffic.

Empowering Cloud Performance

Despite large investments into Cloud first strategies and SaaS applications, many enterprises are still experiencing inconsistent network performance that impacts employees productivity and experience. Enhanced Internet tackles this issue by improving the consistency and quality of application performance and enables businesses to get the most from their investments in cloud and SaaS strategies.

Companies typically spend approximately €500 per employee per month on cloud based applications. Despite this investment, issues in application performance can arise when their network traffic is impacted by latency, jitter, and poor performing routes. This can have serious implications, such as a decline in employee productivity and poor user experience, which can significantly impact the company’s financial performance.

Leveraging AI and Machine Learning to Improve Efficiencies

Enhanced Internet’s AI capabilities means that customers can experience the agility and accessibility of the public internet, combined with the reliability and consistent performance levels typically expected from a private network or MPLS solution. Expereo’s proprietary AI software does this by combining AI with Machine-Learning to intelligently and proactively route network traffic over the best possible path. For customers, the knowledge extends to predictive routes for specific situation by learning the most common traffic paths for their applications and therefore being ready to predict the path before the traffic is sent.

What businesses now have at their disposal is a self-healing network that can navigate past latency and packet loss caused by network congestion.

Complete visibility from a single login.

Paired with Expereo’s customer experience platform expereoOne, businesses can have complete visibility of the health of their network and transparency showing how Enhanced Internet has improved their application performance all from a single login. In addition to performance data, incident management, order status and invoices at site level, expereoOne displays latency and packet loss statistics, percentage of times routes have been changed and overall quality of service statistics personalized by Top 5 cloud destinations for their business. Complete visibility of how application performance has been improved by Enhanced Internet.

Sander Barens, Chief Product Officer for Expereo, commented: “Unpredictable network performance may not seem, at first, like an urgent threat to your business’ success. That is until you realize the increase demands and pressure it puts on IT teams, the damaging impact it has on business efficiency and hours of productivity downtime. With Cloud applications now laying the groundwork for so many modern businesses, connecting to the public internet with the best possible application user experience is the next logical step for global businesses looking to future proof their operations.

“At Expereo, we’re already using our latest AI solution, Enhanced Internet, to lift several customers into the internet age of enhanced connectivity, with very positive results and have big plans to elevate even more global enterprises into this new era of AI internet connectivity over the coming year.”

Find out more here: Enhanced Internet (expereo.com)

About Expereo

Expereo is the intelligent internet company that connects people, places and things anywhere. Solutions include Global Internet, SD-WAN/SASE, and Enhanced Internet. With an extensive global reach, Expereo is the trusted partner of 60% of Fortune 500 companies. It powers enterprise and government sites in more than 190 countries, with the ability to connect to 600,000 locations worldwide, working with over 4,000 partners to help customers improve productivity and empowering their networks and cloud services with the agility, flexibility and value of the Internet, with optimal network performance.

Expereo was acquired in Feb 2021, by Vitruvian Partners. The international growth capital and buyout firm, acquired a majority shareholding from leading European private equity firm, Seven2.

www.expereo.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240131147075/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye